OGN News and Press, Organon & Co. From 11/15/21

Glenview Capital takes new stakes in CCC Intelligent Solutions (NYSE:CCCS) with 2.41M shares, Willis Towers Watson (NASDAQ:WLTW) with 833K shares, and Organon (NYSE:OGN) with 753K shares. Exits Walgreens Boots Alliance (NASDAQ:WBA), Quantum-Si (NASDAQ:QSI), and Medtronic (NYSE:MDT). Boosts st...

Organon was formed via the spin-out of Merck's Women's Health, Biosimilars and Established Brands divisions - shares began trading in May. On Nov. 11, the company reported Q321 earnings, affirming FY21 guidance for $6.2-$6.3bn. Based on nine-month performance, Organon ought to be ...

Organon & Co. (OGN) Q3 Earnings Conference Call November 11, 2021, 8:30 AM ET Company Participants Kevin Ali – Chief Executive Officer Jennifer Halchak – Vice President, Investor Relations Matt Walsh – Chief Financial Officer Conference Call Participants Chris Schott ...

The following slide deck was published by Organon & Co. in conjunction with their 2021 Q3 earnings call. For further details see: Organon & Co. 2021 Q3 - Results - Earnings Call Presentation

Organon (NYSE:OGN) is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed its full-year guidance. For the quarter, the topline dipped ~1% YoY to $1.6B aft...

Organon (NYSE:OGN) declares $0.28/share quarterly dividend, in line with previous. Forward yield 3.06% Payable Dec. 16; for shareholders of record Nov. 22; ex-div Nov. 19. See OGN Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Organon declares $0.28 div...

Organon (NYSE:OGN): Q3 Non-GAAP EPS of $1.67 beats by $0.23; GAAP EPS of $1.27 beats by $0.07. Revenue of $1.6B (-0.6% Y/Y) beats by $10M. Press Release For further details see: Organon EPS beats by $0.23, beats on revenue

Third quarter 2021 revenue of $1,600 million Net income from continuing operations of $323 million, or $1.27 per diluted share; Adjusted net income from continuing operations of $424 million, or $1.67 per diluted share Adjusted EBITDA of $636 million Board of Dir...

Acquisition adds pipeline of candidates targeting novel treatments in women’s health Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug de...

Organon (NYSE:OGN) is scheduled to announce Q3 earnings results on Thursday, November 11th, before market open. The consensus EPS Estimate is $1.44 and the consensus Revenue Estimate is $1.59B. Organon shares traded ~4% higher after the company swung back to growth with better than&...